Streetbeat News

Products Services

TEM

Tempus AI, Inc., a company leveraging AI for precision medicine, has shown strong growth since its June 2024 listing. It presents a buying opportunity due to its vast data library, advanced AI algorithms, and partnerships with Merck and BioNTech. Despite concerns over profitability and cash burn, its revenue growth and strategic acquisitions make it a compelling long-term investment.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

SER

Serina Therapeutics, a clinical-stage biotechnology company, reported its Q3 2024 financial results. The company is advancing its lead IND candidate SER-252 for advanced Parkinson's disease using its POZ Platform™ technology.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

TRP

TC Energy Corporation will host its annual Investor Day on November 19, 2024, which will be webcasted. This event is an opportunity for investors to gain insights into the company's future plans and strategies.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

NFLX

Netflix's ad-supported subscription tier has reached 70 million global monthly active users, showing significant growth from 40 million in May. This highlights the success of Netflix's advertising strategy.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

DOX

Amdocs has been selected by Vivo to enhance its systems flexibility and operational efficiencies, supporting Vivo's microservices strategy and systems evolution.

Portfolio Pulse from

November 12, 2024 | 10:00 pm

DOX

Amdocs has been selected by Wave Money to enhance its financial services operations in Myanmar using the Amdocs Digital Financial Services platform. This partnership aims to provide Wave Money with a scalable and agile platform to meet market demands and optimize costs.

Portfolio Pulse from

November 12, 2024 | 10:00 pm

SKYH

Sky Harbour Group Corporation (NYSE American: SKYH) reported record Q3 2024 results, highlighting its progress in building a nationwide network of Home-Basing campuses for business aircraft. The company released its unaudited financial results for the three and nine months ended September 30, 2024.

Portfolio Pulse from

November 12, 2024 | 10:00 pm

CYCC

CYCCP

Cyclacel Pharmaceuticals announced its third quarter financial results and provided a business update. The company is focused on developing innovative medicines.

Portfolio Pulse from

November 12, 2024 | 10:00 pm

SNDX

Syndax Pharmaceuticals' Revumenib shows promise in treating relapsed/refractory mNPM1 AML, meeting the primary endpoint in a pivotal phase 2 study. An sNDA is expected in the first half of 2025, with a PDUFA action date set for December 26, 2024, for FDA approval consideration for KMT2Ar Acute leukemia patients.

Portfolio Pulse from

November 12, 2024 | 10:00 pm

DOX

Amdocs has announced enhancements to its MarketONE platform, providing new capabilities for communications service providers to offer personalized and flexible services. This development aims to improve customer retention and capture new revenue opportunities.

Portfolio Pulse from

November 12, 2024 | 9:45 pm